Periorificial dermatitis — SAQ

Stem

A 32-year-old woman presents with a 3-month history of grouped erythematous micropapules and papulopustules around the mouth, nose, and lateral canthi with a background of erythema and fine scale.^[15][9][7] She has applied betamethasone valerate 0.1% cream (a topical corticosteroid) twice daily for 6 months after being prescribed it for "facial eczema" by her GP.^[5][1] Examination shows bilateral, symmetrical, monomorphic 1-2 mm papules and papulopustules in the perioral, perinasal, and periocular zones with a narrow rim (a 1-2 mm Grenz zone) of clinically normal skin between the eruption and the lip margin (the vermilion border is spared).^[9][6][10] The lips are clinically normal. She reports burning and stinging rather than itch. She uses a fluoridated toothpaste^[15][16] and a foaming cleanser. She has no relevant past medical or family history and is not pregnant.

Questions

a) What is the most likely diagnosis and what clinical features support it? (2 marks)

Diagnosis: Periorificial (perioral) dermatitis with iatrogenic topical-corticosteroid trigger — a chronic papulopustular facial dermatitis^[3] characterised by acneiform facial eruptions often with an eczematous appearance;^[1] the strongest evidence supports topical corticosteroid misuse as the principal causative factor.^[1]

Supporting clinical features:

• Distribution: perioral, perinasal, and periocular; bilateral and symmetrical. The perioral region is the most common distribution area, but the disease can also affect the periocular and paranasal skin;^[15] perinasal skin, nostrils and eyelids can be involved.^[9]
• Morphology: monomorphic erythematous papules with papulopustules on a background of erythema — erythematous papules (rarely pustules) near the eyes, nose and mouth in a chronic papulopustular facial dermatitis.^[9][7][3] The eruption consists of characteristic grouped erythematous papules that are often bilateral but may be unilateral;^[15] other clinical findings associated with the condition include scaling, vesicles, and pustules.^[15]
• Symptoms: burning and stinging predominate over itch — patients often report burning or sensitivity in the areas of involvement, although pruritus can also occur.^[15] Patients may also report sensitivity to various skincare products, which may exacerbate the rash.^[15]
• HALLMARK — SPARING OF THE VERMILION BORDER: monomorphic erythematous papules usually leave a 1-2 mm Grenz zone around the red lips unaffected;^[9] a typical narrow spared zone around the edge of the lips is characteristic,^[6] and adult disease most often presents around the mouth with this distinctive sparing of the vermilion border.^[10]
• Trigger history: chronic application of a topical corticosteroid — topical corticosteroid use on the face commonly precedes this condition,^[5] and many patients have had recent exposure to a topical (or less commonly inhaled or systemic) corticosteroid.^[7]
• Perpetuating factors: fluoridated toothpaste;^[15][16] other recognised triggers include cosmetics, sunscreens, and dental materials.^[15]

b) What investigations would you arrange to confirm the diagnosis and to screen for alternative or contributing conditions? (3 marks)

1. None are required in the typical case — periorificial dermatitis is a CLINICAL diagnosis based on morphology, distribution, sparing of the vermilion border, and trigger history: laboratory tests are not helpful,^[7] and biopsy or additional testing is warranted only in atypical cases.^[15] It is important to rule out other acneform diagnoses based on age, clinical history, and presentation of the lesions;^[7] the major differential diagnosis is persistent acne.^[9]
2. Punch biopsy — reserved for diagnostic uncertainty, suspected granulomatous variant (childhood granulomatous periorificial dermatitis, also known as facial Afro-Caribbean childhood eruption, is a distinctive granulomatous form of perioral dermatitis^[13]), suspected sarcoidosis (granulomatous periorificial disease can be confused with sarcoidosis^[28]), or suspected lupus miliaris disseminatus faciei (facial involvement mostly around the eyes and on the eyelids, with epithelioid granulomas and central caseous necrosis in some cases on histopathology^[21]). In this adult woman with a clear trigger, biopsy is not required.^[15]
3. Patch testing — only if allergic contact dermatitis is suspected: dental materials are a recognised trigger,^[15] and confirmed allergic contact stomatitis in women shows the highest sensitisation rates for dental metals (nickel, palladium, amalgam) and for propolis and balsam of Peru.^[26] Patch testing should also be considered if patients do not improve with conventional treatments, to rule out allergic contact dermatitis from skincare or oral care products.^[15] Not required here.
4. Demodex quantification (standardised skin-surface biopsy) — only if rosacea overlap is suspected, since the histology of POD resembles rosacea;^[7] Demodex infestation is defined as at least 5 living parasites/cm2 of skin,^[25] quantified against the normal threshold of 5 D/cm2 by standardised skin-surface biopsy.^[20]
5. Pregnancy test before initiating systemic therapy — tetracyclines are class D drugs, contraindicated in pregnancy and in children under 8 years of age^[17] because of the risk of permanent tooth discolouration and possible impact on fetal bone formation;^[18] isotretinoin is a potent teratogen and contraindicated in pregnancy.^[19]

c) Outline your management plan for this patient. (3 marks)

Step 1 — ZERO THERAPY (the foundation): in mild forms of perioral dermatitis, "zero therapy" is the treatment of choice.^[6]

• Discontinue the topical corticosteroid. Corticosteroid cream can improve the clinical picture, but there is a risk of rebound when treatment is stopped;^[5] if a medium- to high-potency steroid has been used, it may need to be slowly weaned using a low-potency steroid (e.g., hydrocortisone cream).^[15]
• Discontinue all other topical products on the face — cosmetics, sunscreens, and other recognised topical triggers.^[15] Specifically, patients should avoid heavy cosmetics and unnecessary skincare products,^[15] and the combined use of moisturizers and foundations, as well as physical sunscreens, has itself been identified as an underlying etiology in some patients.^[15]
• Switch to a non-fluoride toothpaste — fluorinated toothpaste is a recognised trigger,^[15] and perioral dermatitis has been reported in relation to the use of highly fluoridated toothpaste.^[16]
• COUNSEL on the rebound flare — the rash will likely worsen before it improves: abrupt discontinuation may lead to rebound flaring and patients should be forewarned;^[15] the rebound phenomenon usually develops after cessation of previous topical treatment, so patients with steroid-induced disease need close early follow-up.^[6]

Step 2 — TOPICAL ANTI-INFLAMMATORY (moderate disease): in moderate disease, treatment includes topical metronidazole, erythromycin, and pimecrolimus, whereas in more severe cases the best validated choice is oral tetracycline;^[6] in mild adult disease, topical macrolides, azelaic acid, and calcineurin inhibitors are often used, with oral tetracyclines the treatment of choice in more advanced cases.^[9]

• Topical metronidazole gel or cream — a first-line option^[15] and an effective treatment choice with good evidence;^[5] the 0.75% gel is a formulation evaluated for perioral dermatitis.^[15] OR
• Topical azelaic acid gel — first-line;^[15] one systematic review found it may result in no change in physician- or patient-reported severity after 6 weeks of treatment (low certainty);^[2] OR
• Topical pimecrolimus cream — topical calcineurin inhibitors (tacrolimus, pimecrolimus) can be effective:^[15] complete response was noted in 68.8% of children treated with TCI alone, in 75% treated with TCI and metronidazole, and in 77.8% treated with TCI and a systemic antibiotic,^[8] and pimecrolimus may improve physician-reported severity slightly after 4 weeks (low certainty).^[2] The 1% cream has been evaluated in a randomized, double-blind, vehicle-controlled study in adult patients with perioral dermatitis.^[15]

Step 3 — ORAL TETRACYCLINE (more severe or refractory disease): oral tetracycline reveals the best valid evidence.^[5]

• Tetracycline 250-500 mg twice a day, OR
• Doxycycline 100 mg once a day or twice a day, OR
• Minocycline 100 mg once a day or twice a day.
• Prescribed for an 8 to 12 week tapering course — antibiotics are helpful in this condition for their anti-inflammatory properties.^[15]
• Combination with a topical agent is reasonable: complete response with TCI plus metronidazole (75%) or TCI plus a systemic antibiotic (77.8%) exceeded TCI alone (68.8%) in a pediatric cohort.^[8]
• Counsel on delayed response: oral tetracycline may improve physician-reported severity of POD from day 20 onwards (low certainty evidence),^[2] and topical therapies may not show peak efficacy until 3 months of daily treatment.^[15]

Step 4 — REFRACTORY (rare): systemic isotretinoin should be considered for patients refractory to all standard therapies — complete remission has been achieved in a recalcitrant case, with sustained disease control on low-dose isotretinoin maintenance —^[6][11] but isotretinoin is a potent teratogen and is CONTRAINDICATED in pregnancy.^[19] Emerging option: topical roflumilast 0.3% cream once daily (a cream approved in 2022 for chronic plaque psoriasis) cleared one case in 5 days, without recurrence 11 months after treatment initiation.^[10] Specialist referral.

d) What are the key complications and prognostic factors? (2 marks)

Complications:

• Rebound flare and deterioration on steroid withdrawal — although lesions may be initially responsive to steroids, disease often rebounds after discontinuing therapy, potentially leading to chronic, recurrent disease or a granulomatous variant;^[7][15] the rebound phenomenon usually develops after cessation of previous topical treatment.^[6]
• Topical steroid-damaged/dependent face (TSDF) — abuse of topical corticosteroids (and "fairness creams") on the face causes a spectrum of adverse effects: most frequently atrophy, striae, rosacea, perioral dermatitis, acne, and purpura;^[22][4] less frequently hypertrichosis, pigmentation alterations, delayed wound healing, and exacerbation of skin infections;^[4] systemic reactions such as hyperglycemia, glaucoma, and adrenal insufficiency have also been reported after topical application.^[4]
• Iatrogenic harm from misdiagnosis — clinicians often misdiagnose perioral dermatitis and inappropriately prescribe topical corticosteroids, which worsen the condition over time.^[15]
• Psychosocial burden — recognised complications include emotional distress due to the chronicity of the disease and poor quality of life due to sometimes disfiguring lesions on the face.^[15]

Prognostic factors:

• Severity-appropriate treatment and adherence to zero therapy — zero therapy in mild disease; topical metronidazole, erythromycin, or pimecrolimus in moderate disease; oral tetracycline in a subantimicrobial dose until complete remission in more severe disease.^[6]
• Trigger avoidance — no facial topical corticosteroid; fluoridated toothpaste, cosmetics, sunscreens, and dental materials are recognised triggers.^[15]
• Cessation of the offending agent — in some patients the rash may resolve completely after discontinuation of an offending agent, including topical steroids and skincare products;^[15] frequently, however, perioral dermatitis is a chronic relapsing condition that often requires long-term treatment.^[15]
• Expected time course by severity — an 8 to 12 week tapering oral course is standard;^[15] physician-reported improvement may appear from day 20 onwards (low certainty);^[2] topical therapies may not show peak efficacy until 3 months of daily treatment.^[15]
• Granulomatous variant (FACE) — typically persists for several months but resolves without scarring;^[13] it is ultimately self-limited,^[28] although scarring occurred in 14.6% of moderate-to-severe cases in one pediatric cohort.^[23]
• Pregnancy / lactation — options narrow: tetracyclines are contraindicated in children younger than 8, nursing mothers, and pregnant females, when erythromycin 250 mg to 500 mg daily can be used as an alternative;^[15] isotretinoin is contraindicated in pregnancy.^[19]
• Recurrence — the condition often worsens with steroid withdrawal and can pursue a chronic, recurrent course.^[15][6]

Time to resolution: weeks to months for most patients (8-12 week tetracycline tapering course; topical peak efficacy may take up to 3 months of daily treatment);^[15] the granulomatous variant typically runs for several months.^[13]

References24ShowHide

1. [1]Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management J Cosmet Dermatol, 2021.PMID 33751778
2. [2]Gray NA, Tod B, Rohwer A, et al. Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review J Eur Acad Dermatol Venereol, 2022.PMID 34779023
3. [3]Acevedo-Fontanez LA, Sánchez-Feliciano A, Ershadi S, et al. Periorificial dermatitis: Pathophysiology, diagnosis, and management J Am Acad Dermatol, 2026.PMID 41197738
4. [4]Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids J Am Acad Dermatol, 2006.PMID 16384751
5. [5]Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options Am J Clin Dermatol, 2014.PMID 24623018
6. [6]Mokos ZB, Kummer A, Mosler EL, et al. Perioral dermatitis: still a therapeutic challenge Acta Clin Croat, 2015.PMID 26415314
7. [7]Kellen R, Silverberg NB. Pediatric periorificial dermatitis Cutis, 2017.PMID 29360899
8. [8]Ollech A, Yousif R, Kruse L, et al. Topical calcineurin inhibitors for pediatric periorificial dermatitis J Am Acad Dermatol, 2020.PMID 32032693
9. [9]Chiriac A, Chiriac AE, Madke B, et al. Periorificial dermatitis in infants and preschoolers - a narrative review Eur J Pediatr, 2025.PMID 39825187
10. [10]Domingues E. The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission J Clin Aesthet Dermatol, 2026.PMID 42239843
11. [11]Guarda D, Marquez P, Bascuñan G, Montane C. Recalcitrant Perioral Dermatitis Successfully Controlled With Low-Dose Isotretinoin: A Case Report Cureus, 2026.PMID 42037824
12. [13]Kim YJ, Shin JW, Lee JS, et al. Childhood granulomatous periorificial dermatitis Ann Dermatol, 2011.PMID 21909215
13. [15]Tolaymat L, Syed HA, Hall MR. Perioral Dermatitis StatPearls [Internet], 2026.PMID 30247843
14. [16]Peters P, Drummond C. Perioral dermatitis from high fluoride dentifrice: a case report and review of literature Aust Dent J, 2013.PMID 23981221
15. [17]Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation? Expert Opin Drug Saf, 2016.PMID 26680308
16. [18]Smith GN, Gemmill I, Moore KM. Management of tick bites and lyme disease during pregnancy J Obstet Gynaecol Can, 2012.PMID 23231847
17. [19]Ivask M, Kurvits K, Uusküla M, et al. Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia Drugs Real World Outcomes, 2024.PMID 37462893
18. [20]Forton F, Seys B, Marchal JL, et al. Demodex folliculorum and topical treatment: acaricidal action evaluated by standardized skin surface biopsy Br J Dermatol, 1998.PMID 9580800
19. [21]Nasimi M, Bandani S, Kamyab K, et al. Clinical and Histopathological Insights Into Lupus Miliaris Disseminatus Faciei: A Review of 70 Cases J Cutan Pathol, 2025.PMID 39945109
20. [22]Sethi P, Maheshwari K, Arora E, et al. Topical Steroid and Fairness Cream Abuse in Facial Dermatoses: A Cross-Sectional Study at a Tertiary Care Center in Western Uttar Pradesh Cureus, 2026.PMID 41959968
21. [23]Xiao Y, He J, Chen A, et al. Management of childhood granulomatous periorificial dermatitis with clarithromycin: A retrospective cohort study JAAD Int, 2025.PMID 41079392
22. [25]Aksu Arıca D, Ozturk Topcu T, Baykal Selçuk L, et al. Assessment of demodex presence in acne-like rash associated with cetuximab Cutan Ocul Toxicol, 2017.PMID 27802779
23. [26]Forkel S, Schubert S, Corvin L, et al. Contact allergies to dental materials in patients Br J Dermatol, 2024.PMID 38123140
24. [28]Lucas CR, Korman NJ, Gilliam AC. Granulomatous periorificial dermatitis: a variant of granulomatous rosacea in children? J Cutan Med Surg, 2009.PMID 19298782